S100A8 (rs3806232) gene polymorphism and S100A8 serum level in psoriasis vulgaris patients: A preliminary study.
calprotectin
gene polymorphism
psoriasis vulgaris
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
06
02
2022
received:
20
09
2021
accepted:
17
03
2022
pubmed:
23
3
2022
medline:
3
11
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
S100A8 single nucleotide polymorphism (SNP) and S100A8 blood level are related to many inflammatory disorders with no available conclusion in psoriasis. The aim of this study was to evaluate the possible role of S100A8 in psoriasis pathogenesis through analyzing its S100A8 (rs3806232) gene polymorphism and S100A8 serum level in psoriasis vulgaris patients, in addition to correlate the detected results with severity psoriasis in those patients. This case-control study was conducted on 50 patients having psoriasis vulgaris, and 26 controls. Severity of psoriasis was evaluated using psoriasis area and severity index (PASI) score. S100A8 serum level and S100A8 (rs3806232) SNP were evaluated by ELISA and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) respectively. Serum S100A8 level was significantly higher in psoriatic patients than controls and was positively correlated with PASI score (r = 0.826, p < 0.001). S100A8 (rs3806232) AA genotype and A allele were significantly increased among psoriasis patients than controls (p < 0.001) increasing risk of psoriasis development by about 5, 12, and 6 times than AG, GG, and G alleles. AA genotype was significantly associated with psoriasis severity (p = 0.005) and high S100A8 serum levels (p = 0.018). Circulating S100A8 could associated with disease severity and have an active role in psoriasis pathogenesis. S100A8 (rs3806232) SNP (AA genotype and A allele) might contribute to development and severity of psoriasis in the Egyptian population.
Sections du résumé
BACKGROUND
BACKGROUND
S100A8 single nucleotide polymorphism (SNP) and S100A8 blood level are related to many inflammatory disorders with no available conclusion in psoriasis.
AIM
OBJECTIVE
The aim of this study was to evaluate the possible role of S100A8 in psoriasis pathogenesis through analyzing its S100A8 (rs3806232) gene polymorphism and S100A8 serum level in psoriasis vulgaris patients, in addition to correlate the detected results with severity psoriasis in those patients.
METHODS
METHODS
This case-control study was conducted on 50 patients having psoriasis vulgaris, and 26 controls. Severity of psoriasis was evaluated using psoriasis area and severity index (PASI) score. S100A8 serum level and S100A8 (rs3806232) SNP were evaluated by ELISA and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) respectively.
RESULTS
RESULTS
Serum S100A8 level was significantly higher in psoriatic patients than controls and was positively correlated with PASI score (r = 0.826, p < 0.001). S100A8 (rs3806232) AA genotype and A allele were significantly increased among psoriasis patients than controls (p < 0.001) increasing risk of psoriasis development by about 5, 12, and 6 times than AG, GG, and G alleles. AA genotype was significantly associated with psoriasis severity (p = 0.005) and high S100A8 serum levels (p = 0.018).
CONCLUSIONS
CONCLUSIONS
Circulating S100A8 could associated with disease severity and have an active role in psoriasis pathogenesis. S100A8 (rs3806232) SNP (AA genotype and A allele) might contribute to development and severity of psoriasis in the Egyptian population.
Substances chimiques
Calgranulin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4974-4982Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris-Part 1: Treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461-2498.
Hongyan Chen CX, Jin Q, Liu Z. Review article S100 protein family in human cancer. Am J Cancer Res. 2014;4(2):89-115.
Summerton CB, Longlands MG, Wiener K, Shreeve DR. Faecal calprotectin: A marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:841.
Voss A, Gescher K, Hensel A, Nacken W, Zänker KS, Kerkhoff C. Double-stranded RNA induces S100 gene expression by a cycloheximide-sensitive factor. FEBS Lett. 2012;586(2):196-203.
Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:628-637.
Yen T, Harrison CA, Devery JM, et al. Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. Blood. 1997;90:4812-4821.
Van Lent PL, Grevers L, Blom AB, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis. 2008;67(12):1750-1758.
Baillet A, Trocme C, Berthier S, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology. 2010;49:671-682.
Soyfoo MS, Roth J, Vogl T, Pochet R, Decaux G. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol. 2009;36:2190-2194.
Molavi M, Fakheri H, Bahari A, et al. Evaluating the association between genetic polymorphisms of calprotectin and inflammatory bowel diseases. Med J Mashhad Univer Med Sci. 2015;58(1):13-20.
Sun X, Meng H, Shi D, et al. Analysis of plasma calprotectin and polymorphisms of S100A8 in patients with aggressive periodontitis. J Periodontal Res. 2011;46(3):354-360.
Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10):e0164080.
Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194-199.
Li Q, Meng H, Zhang L, et al. Correlation between single nucleotide polymorphisms in a calprotectin subunit gene and risk of periodontitis in a Chinese population. Ann Hum Genet. 2007;71(3):312-324.
Qian M, Song NJ. Serum calprotectin correlates with risk and disease severity in psoriasis patients and the decrease of calprotectin predicts better response to tumor necrosis factor inhibitors. Eur Rev Med Pharmacol Sci. 2018;22(13):4299-4309.
Guzel S, Erfan G, Kulac M, Guzel EC, Kucukyalcin V, Kaya S. Chemerin and calprotectin levels correlate with disease activity and inflammation markers in psoriasis vulgaris. DermatolSinica. 2015;33(1):1-4.
Zaki AM, Amer MA, Mohamed NM, Abdelkhalik MA. Evaluation of serum level of calprotectin in patients with psoriasis and its relation to the clinical severity of the disease. Egypt J Hosp Med. 2019;76(4):3919-3923.
Elwan SA, El-Saadany HM, El-Banna HS, et al. Serum calprotectin as a potential biomarker for subclinical enthesitis in psoriatic patients. Egypt Rheumatol. 2021;43(3):241-245.
Wilsmann-Theis D, Wagenpfeil J, Holzinger D, et al. Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity. J Eur Acad Dermatol Venereol. 2016;30(7):1165-1170.
Di Meglio P, Duarte JH, Ahlfors H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity. 2014;40(6):989-1001.
Capon F, Novelli G, Semprini S, et al. Searching for psoriasis susceptibility genes in Italy: Genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol. 1999;112(1):32-35.
Semprini S, Capon F, Tacconelli A, et al. Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees. Hum Genet. 2002;111(4-5):310-313.
Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889-901.
Chen J, Zhu Z, Li Q, et al. Neutrophils enhance cutaneous vascular dilation and permeability to aggravate psoriasis by releasing matrix metallopeptidase 9. J Invest Dermatol. 2021;141(4):787-799.
Zdanowska N, Kasprowicz-Furmańczyk M, Placek W, Owczarczyk-Saczonek A. the role of chemokines in psoriasis-An overview. Medicina. 2021;57(8):754.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.
Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31(2):331-341.
Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic TH 17 cells in the absence of TGF-β signalling. Nature. 2010;467(7318):967-971.
Cai Y, Xue F, Fleming C, et al. Differential developmental requirement and peripheral regulation for dermal Vγ4 and Vγ6T17 cells in health and inflammation. Nat Commun. 2014;5(1):1-4.
El-Darouti M, Hay RA. Psoriasis: Highlights on pathogenesis, adjuvant therapy and treatment of resistant and problematic cases (part I). J Egypt Women Dermatol Soc. 2010;7:64-67.
Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: A novel group of damage associated molecular pattern molecules. J Leukoc Biol. 2007;81:28-37.
Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthr Rheum. 2003;48(6):1676-1685.
Sarkar D, Fisher PB. Molecular mechanisms of aging-associated inflammation. Cancer Lett. 2006;236(1):13-23.
Källberg E, Vogl T, Liberg D, et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS One. 2012;7(3):e34207.
Pischon N, Pischon T, Kröger J, et al. Association among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontol. 2008;79(6):979-986.
Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet. 1997;6(8):1349-1356.
Fiorino G, Omodei PD. Psoriasis and inflammatory bowel disease: Two sides of the same coin? J Crohns Colitis. 2015;1(1):697-698.